Published Monday, October 19, 2020


October 19, 2020 – WEST PALM BEACH, FL – EXUMA Biotech, a clinical-stage biotechnology company discovering and developing Chimeric Antigen Receptor (CAR)-T cell products and delivery solutions for liquid and solid tumors, announced today the opening of its new West Palm Beach laboratories. The Business Development Board of Palm Beach County (BDB) facilitated the expansion through expedited permitting and also showcased the competitive advantages of the local life sciences industry to EXUMA, resulting in a new 6,500 square-foot lab in West Palm Beach, FL. EXUMA’s expansion will add to an existing workforce, with the newest hire recruited from New York, Dr. Sid Kerkar.

About the Expansion:

  • EXUMA Biotech built the new research laboratories at 625 N. Flagler in West Palm Beach
  • EXUMA West Palm Beach Lab is working on CAR-T discovery and development
  • The facility is 6,500 square feet
  • The expansion will result in new jobs for the local area
  • The BDB assisted EXUMA with the opening

“While it was challenging to build this lab during the middle of the COVID-19 pandemic, we are grateful that Business Development Board of Palm Beach County was able to assist us in getting the lab up and running in record time without any major setbacks. We continue to enjoy our relationship with the local biotech community and our neighbors in West Palm. We are truly excited about the R&D being done in cell therapy through our global operations and the potential therapies for cancer’s most critical patients,” said EXUMA Biotech Chairman and CEO Dr. Gregory Frost, Ph.D.

“EXUMA West Palm Beach Lab will work on CAR-T discoveries and developments to create new treatment products for cancer patients. With Palm Beach County’s collaborative life science industry, we knew the lab would be a perfect fit. Thank you to the City of West Palm Beach for helping us with expedited permitting,” said Kelly Smallridge, President and CEO of the Business Development Board of Palm Beach County.

In the fight against cancer, EXUMA’s global teams are collaborating to develop a first-of-its-kind “off the shelf” treatment, making same-day CAR-T a reality for all cancer patients. In fact, the new West Palm Beach location recently hired Dr. Sid Kerkar, Vice President of Oncology and Research & Development, to oversee the biotech developments in Palm Beach County.

About Dr. Sid Kerkar: Dr. Kerkar joins EXUMA from Eli Lilly and Company, where he served as Associate Vice President Immuno-oncology. Previously, Dr. Kerkar was at Boehringer- Ingelheim Pharmaceuticals from 2017-2019, and from 2016-2017 he was at Bristol Myers Squibb. From 2006-2015, Dr. Kerkar was at the National Institutes of Health where he completed post-doctoral research and clinical fellowships at the National Cancer Institute. His research on the genetic modification of T cells with cytokines to reverse the immuno-suppressive tumor microenvironment advanced from bench to bedside using adoptive T cell therapy. While at the Surgery Branch, Dr. Kerkar provided clinical care to patients on Dr. Steven A. Rosenberg’s cancer immunotherapy protocols.

Dr. Kerkar earned his M.D. from Wayne State University School of Medicine in Detroit, Michigan. He completed general surgery internship at the Detroit Medical Center, and his residency in anatomic pathology at the N.I.H., with a surgical pathology fellowship at the Mayo Clinic.


About EXUMA Biotech Corporation: EXUMA Biotech Corp. is a private Delaware corporation formed in November 2015 with operations in West Palm Beach, Florida, the Cayman Islands and Shanghai, China. EXUMA leverages its globally integrated science, development and informatics teams located across multiple time zones to accelerate the design, high-throughput screening, discovery and development of chimeric antigen receptor T cell (CAR-T) candidates for both solid and liquid tumor malignancies. The company is developing logic gated CAR-T platforms to advance TME-restricted cellular therapies for solid tumors, platforms that will allow for same day, rapid point of care (rPOC) administration for solid or liquid tumors, and highly scalable systems for global therapy deployment, beginning in Asia. Learn more at exumabio.com.


About the Business Development Board: The Business Development Board of Palm Beach County is the official public/private economic development organization for Palm Beach County and Enterprise Florida.  Founded in 1982 as a not-for-profit corporation, our primary purpose is to attract and retain new industry, business investment, high quality jobs and workforce development through corporate relocations, expansions and international trade. During the past five years, the BDB has assisted companies that have created more than 12,822 direct jobs with average salaries greater than $69,062, resulting in more than $777 million in capital investment to Palm Beach County and an economic impact that exceeds $6.87 billion. The BDB’s highest level investor partners include Carrier, Florida Power & Light, LRP Media Group, Stiles Nicholson Foundation, Tortoise Properties, and Wexford Capital. Additional information can be found at the BDB’s website, BDB.org.


Media Contacts: 

Susan Roberts sr@roberts-communications.com

Business Development Board: Kristen Boyd kboyd@bdb.org


#1 Palm Beach County Board of County Commissioners Aerojet Rocketdyne Bank of America Bank United Baptist Health South Florida
Caler, Donten, Levine, Cohen, Porter & Veil, P.A. CareerSource Carrier DePuy Synthes Power Tools, a Johnson & Johnson Company Equestrian Center
Florida Crystals Corporation FPL Greenberg Traurig Gunster Hardrives, Inc.
HCA Palm Beach Hospitals Hedrick Brothers Construction Hospital for Special Surgery J.C. White JP Morgan Chase
LRP Publications Martens Group Minto Communities, LLC NCCI Nova Southeastern University
Palm Beach Aggregates, LLC Palm Beach Park of Commerce PNC Bank Pratt & Whitney (A United Technologies Company) Raymond James Financial Services/Boynton Financial Group, Inc.
RSM South Florida Business & Wealth Magazine South Florida Business Journal Stiles-Nicholson Foundation TD Bank
Tortoise Properties Wells Fargo & Company Wexford Capital